Sanofi-Aventis

Sanofi

Judit Vargane Szeredi

Sandor Batori

Zoltan Kapui

Endre Mikus

Peter Aranyi

Kinga Boer

Geza Timari

Katalin Urban-Szabo

Katalin Gerber

Michel Finet

Lajos T Nagy

Laszlo Balazs

Tibor Szabo

Maria Balogh

Edit Susan

Erzsebet Walcz

Katalin Urban Szabo

Marton Varga

Veronika Bartane Bodor

Mihalyne Santa, Legal Representative

Marianna Kovacs

Agnes Pappne Behr

The present invention relates to the adenosine Areceptor ligands of the general formula (I), within them favourably to the antagonists, to their salts, solvates, N-oxides and isomers, to the pharmaceutical compositions containing the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, to the use of the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, to the preparation of the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, as well as to the new intermediates of the general formula (II), (VI), (XI), (XII) and (XV), and to the preparation thereof.

Compounds

The present invention relates to an adenosine Areceptor ligand of the general formula (I).

Aminoquinoline derivatives and their use as adenosine A3 ligands

The invention relates to a compound of the general formula (I), as defined herein which is useful for the treatment of a pathology in a patient wherein a CCR3 receptor plays a role in the development of the pathology, and pharmaceutical preparations containing such compound. The invention is also directed to a process for preparing the compound of the general formula (I), and intermediate useful in the preparation.

Amino-alkyl amide derivatives as CCR3 receptor ligands

The present invention relates to an adenosine Areceptor ligand of the general formula (I), within those preferably to the antagonists, including a salt, solvate or isomer (tautomer, desmotrop, and optically active isomer) thereof, to a pharmaceutical composition containing the ligand, to the use of the ligand, to its preparation, and intermediates of the ligand of the general formula (II&#x2033;), (III&#x2033;), (IV&#x2033;), (V&#x2033;), (VI&#x2033;), (VII&#x2033;), (VIII&#x2033;) and (XIII&#x2033;) and their preparation.

This invention is directed to a compound of formula (I), wherein R, R, R, R, R, R, R, R, R, R, X, Z, m, n, o, p and r are as defined herein, its preparation, pharmaceutical composition and use as an adenosine Areceptor ligand preferably an antagonist.

Imidazoquinoline derivatives as adenosine A3 receptor ligands

Growing community of inventors

Budapest, Hungary

Judit Vargane Szeredi